Xolair Related Published Studies
Well-designed clinical trials related to Xolair (Omalizumab)
Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. [2008.05]
Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. [2008.02]
Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. [2008]
Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. [2007.10]
Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. [2007.09]
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. [2007.09]
Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. [2007.02]
[Omalizumab as a therapeutic option in atopic eczema : Current evidence and potential benefit.] [2007.02]
[Omalizumab as a therapeutic option in atopic eczema : Current evidence and potential benefit.] [2007.01.20]
Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. [2006.06]
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. [2006.01]
Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma. [2006]
Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. [2005.09]
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. [2005.03]
Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. [2004.09.15]
Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. [2004.09]
Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. [2004.08]
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. [2004.07]
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. [2004.07]
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. [2004.04]
Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. [2004.04]
Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. [2004.04]
Omalizumab inhibits allergen challenge-induced nasal response. [2004.03]
Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. [2004.02]
Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. [2003.12]
Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab). [2003.10]
Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. [2003.08]
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. [2003.08]
Omalizumab is effective in the long-term control of severe allergic asthma. [2003.08]
Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. [2003.05]
Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. [2003.02]
Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. [2003.01]
The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. [2002.11]
Omalizumab improves asthma-related quality of life in children with allergic asthma. [2002.11]
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. [2002.07]
The effect of omalizumab on nasal allergic inflammation. [2002.07]
Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. [2001.12.19]
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. [2001.08]
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. [2001.08]
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). [2001.08]
Well-designed clinical trials possibly related to Xolair (Omalizumab)
Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. [2008.04]
The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. [2006.09]
The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. [2004.09]
Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. [2004.07]
The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. [2002.11]
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. [2002.02]
Other research related to Xolair (Omalizumab)
Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. [2008.10]
Treatment of chronic autoimmune urticaria with omalizumab. [2008.09]
Anti-IgE Antibody Therapy for Japanese Cedar Pollinosis: Omalizumab Update. [2008.09]
Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study. [2008.07.25]
Churg-Strauss syndrome associated with omalizumab. [2008.07]
An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. [2008.06]
Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. [2008.06]
The use of omalizumab in asthma. [2008.06]
Reduction of the total IgE level by omalizumab in children and adolescents. [2008.04]
Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis. [2008.04]
Churg-Strauss vasculitis in a patient treated with omalizumab. [2008.03]
Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. [2008.02]
[Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] [2008.01]
Omalizumab: a review of its use in the treatment of allergic asthma. [2008]
[Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine] [2007.12.10]
Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. [2007.12.07]
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. [2007.12]
[Application of humanized Anti-IgE antibodies (omalizumab). A new principle in the treatment of allergic diseases in ENT medicine] [2007.12]
Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. [2007.12]
Use of omalizumab in a severe asthma clinic. [2007.11]
Omalizumab (Xolair) in patients with steroid-resistant asthma: lessons to be learnt. [2007.11]
Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. [2007.11]
CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. [2007.10]
Anti-immunoglobulin E therapy with omalizumab for asthma. [2007.09]
Effect of omalizumab on patients with chronic urticaria. [2007.08]
Predicting and evaluating response to omalizumab in patients with severe allergic asthma. [2007.07]
Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. [2007.07]
The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study. [2007.06]
The effects of repeat omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen. [2007.05]
Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. [2007.05]
The appropriate omalizumab patient. [2007.05]
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. [2007.05]
[Omalizumab (Xolair). Product description] [2007.03.12]
Predicting and evaluating response to omalizumab in patients with severe allergic asthma. [2007.03.03]
Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. [2007.02]
Omalizumab decreases nonspecific airway hyperresponsiveness in vitro. [2007.02]
Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). [2007.01]
Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. [2006.12]
Improvement in quality of life with omalizumab in patients with severe allergic asthma. [2006.11]
Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. [2006.11]
Improvement of asthma control with omalizumab in 2 obese pediatric asthma patients. [2006.09]
Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. [2006.09]
[Omalizumab in severe asthma--case report] [2006.08]
The role of omalizumab in the treatment of severe allergic asthma. [2006.07]
[Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma] [2006.05]
Characterization of an anaphylactoid reaction to omalizumab. [2006.04]
Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). [2006.04]
Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. [2006.03.08]
Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. [2006.02]
Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. [2006.02]
Treatment of recalcitrant atopic dermatitis with omalizumab. [2006.01]
IgE, allergic diseases, and omalizumab. [2006]
[Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma] [2006]
Effect of Omalizumab on Adenosine 5'-Monophosphate Responsiveness in Subjects with Allergic Asthma. [2005.12.21]
Symptom Control and Improved Functioning: The Effect of Omalizumab on Asthma-Related Quality of Life (ARQL). [2005.12]
|
